Mankind Pharma has crossed a market capitalization of ₹1.05 lakh crore. The company continues to post consistent sales growth, and its EBITDA margins have remained stable for the last two years — signaling strong operational performance.
But one key observation caught my eye — and deserves closer attention:
📉 Borrowing has jumped from ₹207 Cr (Mar’24) to ₹8,511 Cr (Mar’25)
📊 Intangible Assets stand at ₹15,987 Cr
📈 Institutional investors (FIIs & DIIs) are steadily increasing their holdings.
🔸 Is this borrowing linked to a strategic acquisition?
🔸 Are these intangible assets generating tangible returns?
🔸 Is this leverage a step toward long-term value creation, or does it pose a financial risk?
📢 What’s your take on this?
Do you see this as aggressive growth or a reason for caution?
💬 Let’s break it down together — share your thoughts in the comments 👇
